The primary aim of this study was to investigate the utility of the post-adjuvant levels of serum CEA and four other serum biomarkers, CA19-9, IL-6, CRP, and YKL-40, as prognostic biomarkers for disease-free survival (DFS) and OS in CRC patients treated with curative intent. The gene discussed is CEACAM5; the disease is colorectal carcinoma.